1. Home
  2. LPLA vs TNGX Comparison

LPLA vs TNGX Comparison

Compare LPLA & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LPLA
  • TNGX
  • Stock Information
  • Founded
  • LPLA 1989
  • TNGX 2014
  • Country
  • LPLA United States
  • TNGX United States
  • Employees
  • LPLA N/A
  • TNGX N/A
  • Industry
  • LPLA Investment Bankers/Brokers/Service
  • TNGX Biotechnology: Pharmaceutical Preparations
  • Sector
  • LPLA Finance
  • TNGX Health Care
  • Exchange
  • LPLA Nasdaq
  • TNGX Nasdaq
  • Market Cap
  • LPLA N/A
  • TNGX 990.5M
  • IPO Year
  • LPLA 2010
  • TNGX N/A
  • Fundamental
  • Price
  • LPLA $229.77
  • TNGX $9.90
  • Analyst Decision
  • LPLA Buy
  • TNGX Strong Buy
  • Analyst Count
  • LPLA 12
  • TNGX 8
  • Target Price
  • LPLA $287.27
  • TNGX $14.86
  • AVG Volume (30 Days)
  • LPLA 1.2M
  • TNGX 851.2K
  • Earning Date
  • LPLA 07-25-2024
  • TNGX 08-05-2024
  • Dividend Yield
  • LPLA 0.54%
  • TNGX N/A
  • EPS Growth
  • LPLA 2.00
  • TNGX N/A
  • EPS
  • LPLA 13.26
  • TNGX N/A
  • Revenue
  • LPLA $10,467,609,000.00
  • TNGX $37,232,000.00
  • Revenue This Year
  • LPLA $18.97
  • TNGX N/A
  • Revenue Next Year
  • LPLA $15.62
  • TNGX $2.40
  • P/E Ratio
  • LPLA $16.67
  • TNGX N/A
  • Revenue Growth
  • LPLA 16.92
  • TNGX 49.72
  • 52 Week Low
  • LPLA $200.18
  • TNGX $2.88
  • 52 Week High
  • LPLA $289.88
  • TNGX $13.03
  • Technical
  • Relative Strength Index (RSI)
  • LPLA 33.96
  • TNGX 58.70
  • Support Level
  • LPLA $202.34
  • TNGX $8.93
  • Resistance Level
  • LPLA $284.59
  • TNGX $10.05
  • Average True Range (ATR)
  • LPLA 10.97
  • TNGX 0.61
  • MACD
  • LPLA -4.45
  • TNGX -0.01
  • Stochastic Oscillator
  • LPLA 37.50
  • TNGX 87.76

About TNGX Tango Therapeutics Inc.

Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.

Share on Social Networks: